BROADWOOD PARTNERS, L.P. - 10 Feb 2026 Form 4 Insider Report for Insight Molecular Diagnostics Inc. (IMDX)

Role
10%+ Owner
Signature
Broadwood Partners, L.P., By Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President
Issuer symbol
IMDX
Transactions as of
10 Feb 2026
Net transactions value
+$2,999,999
Form type
4
Filing time
12 Feb 2026, 19:49:56 UTC
Previous filing
13 Jan 2026
Next filing
13 Mar 2026
SEC
View on sec.gov

Reporting Owners (3)

Name Relationship Address Signature Signature date CIK
BROADWOOD PARTNERS, L.P. 10%+ Owner C/O BROADWOOD CAPITAL, INC., 156 WEST 56TH STREET, 3RD FLOOR, NEW YORK Broadwood Partners, L.P., By Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President 12 Feb 2026 0001278386
BROADWOOD CAPITAL INC 10%+ Owner 156 WEST 56TH STREET, 3RD FLOOR, NEW YORK Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President 12 Feb 2026 0001278387
Bradsher Neal C 10%+ Owner C/O BROADWOOD CAPITAL, INC., 156 WEST 56TH STREET, 3RD FLOOR, NEW YORK /s/ Neal C. Bradsher 12 Feb 2026 0001278388

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMDX Common Stock, no par value Purchase $2,999,999 +521,739 +4.6% $5.75 11,931,839 10 Feb 2026 Direct F1, F3
transaction IMDX Common Stock, no par value Purchase $0 0 0% $0.000000* 11,931,839 10 Feb 2026 Footnote F1, F3
holding IMDX Common Stock, no par value 157 10 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMDX Warrant to Purchase Common Stock 150,093 10 Feb 2026 Common Stock 150,093 $30.60 Direct F1, F4
holding IMDX Warrant to Purchase Common Stock 150,093 10 Feb 2026 Common Stock 150,093 $30.60 See Footnote F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2 These securities are directly owned by Neal C. Bradsher.
F3 On February 10, 2026, Broadwood Partners entered into a Securities Purchase Agreement with Insight Molecular Diagnostics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 521,739 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a registered direct offering for a total purchase price of $2,999,999, or $5.75 per Common Share.
F4 These warrants are currently exercisable.